Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | -0.73% | -16.00% | -28.91% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 164M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
Net cash position 2024 * | 164M | Net cash position 2025 * | 269M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-1.88
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.76% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | -0.73% | ||
1 week | -16.00% | ||
Current month | -7.14% | ||
1 month | -21.78% | ||
3 months | -39.06% | ||
6 months | +1.49% | ||
Current year | -28.91% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 56 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 2.73 | -0.73% | 323,854 |
24-06-03 | 2.75 | -6.46% | 335,602 |
24-05-31 | 2.94 | -1.34% | 371,129 |
24-05-30 | 2.98 | -2.30% | 396,339 |
24-05-29 | 3.05 | -6.15% | 319,337 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.91% | 165M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- ABOS Stock